biotech / news / / Benzinga
Clear cell RCC is the most common form of kidney cancer, accounting for roughly 75–80% of cases.
The Keytruda-Lenvima-Welireg triplet regimen failed to meet PFS and OS endpoints in trial.
KEY POINTS
- MK-1308A plus Lenvima also did not outperform Keytruda plus Lenvima in the interim analysis.
- Safety profiles for the new regimens matched those seen in previous studies, with no new concerns.
- Analysts suggest these results may open opportunities for zanzalintinib-based HIF-2 alpha regimens in RCC.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →